Global review finds camel nasal bot fly burden remains high

A newly published systematic review in Frontiers in Veterinary Science suggests camel nasal bot fly infestation remains a major, under-synthesized health issue across camel-rearing regions. Reviewing 41 epidemiological studies from 1980 through 2025, the authors estimated a pooled global prevalence of Cephalopina titillator infestation of 67% across 18,959 camels from 11 countries. The paper was published July 8, 2026, and positions itself as the first global meta-analysis focused specifically on the parasite’s prevalence and epidemiologic distribution. (frontiersin.org)

That matters because the existing literature has largely been regional, making it difficult for clinicians, herd health programs, and policymakers to judge how widespread the problem really is. The review was conducted under PRISMA 2020 guidelines and prospectively registered in PROSPERO, which adds methodological weight. The authors searched PubMed/MEDLINE, Scopus, Web of Science, Google Scholar, and CAB Direct, aiming to create a baseline for surveillance planning and region-specific control strategies. (frontiersin.org)

The topline number, though, comes with an important caveat. Statistical heterogeneity was extremely high at I² = 99.1%, and the authors explicitly warn that the pooled estimate should be treated as a broad epidemiologic summary rather than a universally applicable prevalence figure. In practical terms, that means veterinarians shouldn’t read 67% as a field-ready benchmark for every herd or country. Instead, the paper points to strong local effects from geography, climate, husbandry, study design, and diagnostic methods. (frontiersin.org)

Regional subgroup findings illustrate that variation clearly. Asia showed the highest pooled estimate at 79%, although with a very wide confidence interval, reflecting limited data. Africa followed at 75%, the Middle East at 57%, and Australia was represented by a single study at 49%. By species, prevalence estimates were broadly similar: 67% for Camelus dromedarius and 79% for Camelus bactrianus, but the difference was not statistically significant, and the bactrian estimate was imprecise because relatively few studies were available. (frontiersin.org)

Outside the meta-analysis itself, recent and prior research helps explain why this parasite still deserves attention. C. titillator larvae develop in the nasal passages, paranasal sinuses, and pharyngeal cavities of camels. Clinical and postmortem work has associated infestation with restlessness, nasal discharge, sneezing, snorting, elevated respiratory rate, mucosal congestion, bloody mucus, and occasional neurologic signs that can complicate diagnosis. Separate studies have also described adverse effects on breathing, milk production, fertility, and tissue integrity. (frontiersin.org)

There’s also a diagnostic gap. One 2022 study from Egypt noted that diagnosis is still primarily postmortem, while evaluating ELISA-based detection of C. titillator-specific antibodies as a possible aid for live-animal identification. That kind of work matters because better ante-mortem detection could help veterinarians intervene earlier, avoid confusion with neurologic disease, and build more reliable surveillance programs in endemic regions. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, this paper is less about a surprise emergence event and more about scale. It argues that camel nasal myiasis is common enough to merit routine consideration in respiratory disease workups, herd health planning, and production-loss investigations in camel systems. The lack of a significant difference by study period suggests the burden hasn’t clearly fallen over time, while the strong regional signal supports tailored control measures rather than one-size-fits-all recommendations. For practices serving pastoralist or commercial camel operations, the findings strengthen the case for locally informed parasite surveillance, seasonality tracking, and preventive planning. (frontiersin.org)

What to watch: The next step will likely be more standardized prevalence studies, especially in underrepresented regions and in bactrian camels, along with validation of practical live-animal diagnostics and region-specific control programs. Given the high heterogeneity in the current evidence, the most useful future data may come not from another global average, but from better local epidemiology tied to management conditions and clinical outcomes. (frontiersin.org)